Ajulemic acid, a synthetic cannabinoid acid, induces an antiinflammatory profile of eicosanoids in human synovial cells

To better understand mechanisms whereby Ajulemic acid (AjA), a synthetic antiinflammatory cannabinoid, promotes resolution of acute and chronic inflammation in animal models, we investigated its influence on cyclooxygenase 2 (COX2) expression and eicosanoid production in human fibroblast-like synovi...

Full description

Saved in:
Bibliographic Details
Published inLife sciences (1973) Vol. 83; no. 19; pp. 666 - 670
Main Authors Stebulis, Judith A., Johnson, David R., Rossetti, Ronald G., Burstein, Sumner H., Zurier, Robert B.
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier Inc 07.11.2008
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:To better understand mechanisms whereby Ajulemic acid (AjA), a synthetic antiinflammatory cannabinoid, promotes resolution of acute and chronic inflammation in animal models, we investigated its influence on cyclooxygenase 2 (COX2) expression and eicosanoid production in human fibroblast-like synovial cells (FLS). FLS isolated from tissue obtained at joint replacement surgery or cultured from synovial fluid were treated for 60 min with AjA (10–30 μM), then stimulated with tumor necrosis factor α (TNFα). COX2 mRNA was measured by hybridization/colorimetric assay of whole cell lysates collected 4 h after stimulation. To determine effects on arachidonic acid release, FLS were incubated with 14C-arachidonic acid for 20 h then treated with AjA (8–32 μM). Arachidonic acid release was measured by scintillation counting. Prostaglandins (PG) were measured by enzyme linked immunosorbent assay (ELISA) in cell supernatants collected 4 and 24 h after stimulation. AjA increased the steady state levels of COX2 mRNA in and arachidonic acid release from FLS. Treatment of FLS with AjA increased 15-deoxy-delta 12,14-PGJ 2 (15d-PGJ 2) production in a concentration dependent manner, but did not affect PGE 2 production significantly. The capacity of AjA to increase selectively and markedly 15d-PGJ 2, an eicosanoid which facilitates resolution of inflammation, suggests that AjA may have value as a therapeutic agent for the treatment of rheumatoid arthritis (RA) and other diseases characterized by acute and chronic inflammation.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0024-3205
1879-0631
DOI:10.1016/j.lfs.2008.09.004